TrialJournal for immunotherapy of cancer2021

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.

Yousef Zakharia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.